Different effects of a CD14 gene polymorphism on disease outcome in patients with alcoholic liver disease and chronic hepatitis C infection

Table 1 Frequency of (–159) CD14 genotypes (%) in patients with chronic alcohol abuse and cirrhosis, compared to alcoholics without clinical or sonomorphological signs of cirrhosis and controls

	CD14 genotype frequency
	CC	CT	TT
Alcoholics with cirrhosis (n=62)	5 (8.1%)	32 (51.6%)	25 (40.3%)
Alcoholics w/o cirrhosis (n=118)	32 (27.1%)	58 (49.2%)	28 (23.7%)
Controls (n=247)	64 (25.6%)	128 (51.8%)	55 (22.3%)

Table 2 Clinical and biological characteristics of 121 patients with chronic hepatitis C infection according to CD14 –159 genotypes (TT vs CC and CT)

Clinical and biological characteristics	All patients	CD14 –159 genotype
		TT	CC or CT
Age (yr; mean±SD)	37.2±11.5	38.0±12.3	37.1±11.4
Male gender (%)	66.1	58.6	68.5
HCV transmission route (%)
- i.v. drug use	25.6	24.1	26.1
- Post-transfusion	15.7	17.2	15.2
- Other factors or unknown	58.7	58.6	58.7
HCV genotypes (%)
- Type 1	64.5	58.7	66.3
- Type 3	27.3	34.5	25
- Others than type 1 or 3	8.3	6.9	8.7
Viral load
(106 copies/mL; median)	1.7	2	1.6
Initial virological response to anti-HCV treatment1 (%)	65.9	66.7	65.7

¹HCV-RNA negative, 3 mo after the start of antiviral therapy; data available from 91/121 patients.